当前慢性特发性便秘与便秘型肠易激综合征药物治疗的作用机制
本综述总结了慢性特发性便秘和便秘型肠易激综合征常用非处方与处方治疗的作用机制,阐述各机制如何贡献于疗效与安全性。部分泻药如刺激性泻药可增加排便频率但可能不缓解甚至加重腹部症状,而鸟苷酸环化酶C激动剂等处方药可改善肠道症状并减少内脏高敏感。
要点
- 刺激性泻药可增加排便频率,但可能不缓解甚至加重腹部症状。
- 鸟苷酸环化酶C激动剂等处方药可改善肠道症状并减少内脏高敏感。
- 理解各治疗的作用机制有助于预测疗效并优化治疗结果。
核心结论
- 理解每种治疗的作用机制有助于预测预期反应并优化治疗结果。
研究设计与样本
- 综述,总结慢性特发性便秘和便秘型肠易激综合征常用非处方与处方治疗的作用机制。
主要发现
- 刺激性泻药可增加排便频率,但可能不缓解甚至加重腹部症状。
- 鸟苷酸环化酶C激动剂等处方药可改善肠道症状并减少内脏高敏感。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple therapeutic agents are currently available for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. A better understanding of the mechanism of action of each treatment provides important insights into expected responses and is key to optimizing treatment outcomes. Some constipation treatments, such as stimulant laxatives, may increase bowel movement frequency but are ineffective at relieving, and may even exacerbate, abdominal symptoms. On the contrary, prescription treatments, such as the guanylyl cyclase-C agonists, for example, may improve bowel symptoms and reduce visceral hypersensitivity. This review summarizes the mechanisms of action of commonly used over-the-counter and prescription therapies for chronic idiopathic constipation and irritable bowel syndrome with constipation, outlining how these mechanisms contribute to the efficacy and safety of each treatment option.
引用
- Sayuk GS, Waldman SA, Brenner DM, et al. Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation. Am J Gastroenterol. 2022. PMID: 35354770. doi:10.14309/ajg.0000000000001687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。